Effectiveness of statins as prevention in people with gout: a population-based cohort study

dc.contributor.author
Garcia Gil, Maria
dc.contributor.author
Comas Cufí, Marc
dc.contributor.author
Ramos, Rafel
dc.contributor.author
Martí, Ruth
dc.contributor.author
Alves-Cabratosa, Lia
dc.contributor.author
Parramon, Dídac
dc.contributor.author
Prieto-Alhambra, Daniel
dc.contributor.author
Baena Díez, Jose M.
dc.contributor.author
Salvador-González, Betlem
dc.contributor.author
Elosua Llanos, Roberto
dc.contributor.author
Dégano, Irene R.
dc.contributor.author
Marrugat de la Iglesia, Jaume
dc.contributor.author
Grau Magaña, Maria
dc.date.issued
2020-02-06T07:26:51Z
dc.date.issued
2020-02-06T07:26:51Z
dc.date.issued
2019
dc.identifier
Garcia-Gil M, Comas-Cufí M, Ramos R, Martí R, Alves-Cabratosa L, Parramon D. et al. Effectiveness of statins as prevention in people with gout: a population-based cohort study. J Cardiovasc Pharmacol Ther. 2019 Nov;24(6):542-50. DOI: 10.1177/1074248419857071
dc.identifier
1074-2484
dc.identifier
http://hdl.handle.net/10230/43498
dc.identifier
http://dx.doi.org/10.1177/1074248419857071
dc.description.abstract
Background: Cardiovascular guidelines do not give firm recommendations on statin therapy in patients with gout because evidence is lacking. Aim: To analyze the effectiveness of statin therapy in primary prevention of coronary heart disease (CHD), ischemic stroke (IS), and all-cause mortality in a population with gout. Methods: A retrospective cohort study (July 2006 to December 2017) based on Information System for the Development of Research in Primary Care (SIDIAPQ), a research-quality database of electronic medical records, included primary care patients (aged 35-85 years) without previous cardiovascular disease (CVD). Participants were categorized as nonusers or new users of statins (defined as receiving statins for the first time during the study period). Index date was first statin invoicing for new users and randomly assigned to nonusers. The groups were compared for the incidence of CHD, IS, and all-cause mortality, using Cox proportional hazards modeling adjusted for propensity score. Results: Between July 2006 and December 2008, 8018 individuals were included; 736 (9.1%) were new users of statins. Median follow-up was 9.8 years. Crude incidence of CHD was 8.16 (95% confidence interval [CI]: 6.25-10.65) and 6.56 (95% CI: 5.85-7.36) events per 1000 person-years in new users and nonusers, respectively. Hazard ratios were 0.84 (95% CI: 0.60-1.19) for CHD, 0.68 (0.44-1.05) for IS, and 0.87 (0.67-1.12) for all-cause mortality. Hazard for diabetes was 1.27 (0.99-1.63). Conclusions: Statin therapy was not associated with a clinically significant decrease in CHD. Despite higher risk of CVD in gout populations compared to general population, patients with gout from a primary prevention population with a low-to-intermediate incidence of CHD should be evaluated according to their cardiovascular risk assessment, lifestyle recommendations, and preferences, in line with recent European League Against Rheumatism recommendations.
dc.format
application/pdf
dc.format
application/pdf
dc.language
eng
dc.publisher
SAGE Publications
dc.rights
Garcia-Gil M, Comas-Cufí M, Ramos R, Martí R, Alves-Cabratosa L, Parramon D. et al., ffectiveness of statins as prevention in people with gout: a population-based cohort study. J Cardiovasc Pharmacol Ther.Nov;24(6):542-550 Copyright © 2019. DOI: 10.1177/1074248419857071
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Acute myocardial infarction
dc.subject
Cerebrovascular disease
dc.subject
Electronic medical records
dc.subject
Primary care
dc.subject
Statin
dc.title
Effectiveness of statins as prevention in people with gout: a population-based cohort study
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/acceptedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)